Data Article

Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world

Anselm K. Gitta, Dominik Lautsch, Jean Ferrieres, John Kastelein, Heinz Drexel, Martin Horack, Philippe Brudi, Brecht Vanneste, Peter Bramlage, Francois Chazelle, Vasilisa Sazonov, Baishali Ambegaonkar

* Klinikum der Stadt Ludwigshafen, Medizinische Klinik B, Ludwigshafen, Germany
b Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Germany
c Merck & Co., Inc., Kenilworth, NJ, USA
d Toulouse University School of Medicine, Toulouse, France
e Department of Vascular Medicine, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands
f Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria
g Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria
h Private University of the Principality of Liechtenstein, Triesen, Liechtenstein
i Drexel University College of Medicine, Philadelphia, PA, USA
j Institute for Pharmacology and Preventive Medicine, Mahlow, Germany

DOI of original article: http://dx.doi.org/10.1016/j.atherosclerosis.2016.09.004

* Corresponding author.
E-mail address: gitta@klilu.de (A.K. Gitt).

http://dx.doi.org/10.1016/j.dib.2016.09.037
2352-3409/© 2016 The Authors. Published by Elsevier Inc. All rights reserved.
Data presented here refer to 57,885 patients on lipid-lowering statin therapy from the Dyslipidaemia International Study (DYSIS) registry. Subjects were divided into 3 discrete subsets: those at very high-risk, high-risk, and non-high-risk for cardiovascular events, with assigned low density lipoprotein cholesterol (LDL-C) targets of 70 mg/dl, 100 mg/dl and 115 mg/dl, respectively. Overall, the highest proportion of patients meeting their LDL-C target was seen in the UAE and Kuwait (49.5%), while the lowest was seen in Germany (14.3%). The smallest median distance to target was documented in Canada (18.8 mg/dl), and the largest in the Baltics (42.1 mg/dl). Interpretation and discussion of this data can be found in the manuscript entitled “Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients” (Gitt et al., 2016) [1].

© 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Value of the data

- These data are gathered from a large, worldwide registry and insights are therefore applicable to physicians globally.
- As data are stratified by individual country, target attainment within different national healthcare systems can be compared and potential improvements made based on the experience of more successful countries.
- Data can be used as a basis from which to launch further studies investigating optimal treatment regimes for patients at risk of cardiovascular events, both globally and within individual countries.
Table 1 displays the proportion of patients attaining risk based target LDL-C values in a global cohort, overall and divided by country and region of the world. Table 2 displays the median distance to risk based treatment targets in a global cohort, overall and divided by country and region of the world.

### Table 1: Proportions of patients attaining their target LDL-C values.

| Country (n)       | Total        | Very high-risk\(a\) | High-risk\(b\) | Non-high-risk\(b\) | P-value |
|-------------------|--------------|----------------------|----------------|---------------------|---------|
| % (n/N)           | % (n/N)      | % (n/N)              | % (n/N)        |                     |         |
| **Europe/Canada/Israel** |              |                      |                |                     |         |
| Austria (n=881)   | 15.9 (123/772)| 12.9 (85/657)        | 20.7 (6/29)    | 37.2 (32/86)        | < 0.0001|
| Baltics (n = 1797)| 15.9 (282/1779)| 10.9 (151/1386)      | 20.5 (24/117)  | 38.8 (107/276)      | < 0.0001|
| Belgium (n=509)   | 35.7 (310/868)| 21.6 (116/536)       | 40.3 (34/84)   | 64.5 (160/248)      | < 0.0001|
| Canada (n=2436)   | 45.6 (1098/2410)| 40.7 (787/1933)      | 50.3 (79/157)  | 72.5 (232/320)      | < 0.0001|
| Denmark (n=933)   | 37.7 (338/897)| 30.2 (196/650)       | 45.4 (40/108)  | 66.9 (63/93)        | < 0.0001|
| France (n=4192)   | 20.6 (835/4061)| 14.4 (385/2677)      | 16.6 (50/302)  | 37.0 (400/1082)     | < 0.0001|
| Germany (n=4216)  | 14.3 (555/3879)| 11.2 (371/3300)      | 18.9 (44/233)  | 40.5 (140/346)      | < 0.0001|
| Greece (n=755)    | 17.8 (132/741)| 9.2 (42/456)         | 19.1 (9/47)    | 34.0 (81/238)       | < 0.0001|
| Ireland (n=900)   | 43.5 (376/865)| 35.9 (222/618)       | 58.6 (51/87)   | 64.4 (103/160)      | < 0.0001|
| Israel (n=100)    | 29.1 (223/766)| 20.3 (121/597)       | 49.0 (24/49)   | 65.0 (78/120)       | < 0.0001|
| Italy (n=766)     | 30.7 (206/671)| 22.7 (95/419)        | 29.4 (15/51)   | 47.8 (96/201)       | < 0.0001|
| The Netherlands (n=1199)| 30.8 (354/1151)| 27.4 (279/1019) | 34.1 (15/44) | 68.2 (60/88) | < 0.0001|
| Norway (n=957)    | 29.2 (247/847)| 18.5 (112/607)       | 46.2 (48/104)  | 64.0 (87/136)       | < 0.0001|
| Portugal (n=910)  | 20.4 (144/706)| 11.1 (46/415)        | 25.0 (13/52)   | 35.6 (85/239)       | < 0.0001|
| Russia (n=1585)   | 17.0 (189/1114)| 12.2 (118/967)      | 30.3 (10/33)   | 53.5 (61/114)       | < 0.0001|
| Slovakia (n=926)  | 24.5 (226/923)| 16.5 (121/733)       | 37.3 (19/51)   | 61.9 (86/139)       | < 0.0001|
| Slovenia (n=766)  | 23.6 (178/755)| 19.1 (122/640)       | 25.6 (10/39)   | 60.5 (46/76)        | < 0.0001|
| Spain (n=3664)    | 16.7 (380/2483)| 10.1 (221/2186)    | 17.9 (48/268)  | 30.8 (311/1009)     | < 0.0001|
| Sweden (n=958)    | 27.6 (223/807)| 21.4 (141/660)       | 45.3 (34/75)   | 66.7 (48/72)        | < 0.0001|
| UK (n=1315)       | 40.9 (426/1041)| 38.3 (333/922)     | 50.0 (13/26)   | 64.5 (60/93)        | < 0.0001|

### Middle East/Africa

| Egypt (n = 1457)| 18.8 (260/1384)| 13.2 (157/1188)      | 28.2 (11/39)   | 58.6 (92/157)        | < 0.0001|
| Lebanon/Jordan (n=603)| 41.6 (221/531)| 33.0 (120/364)      | 37.1 (13/35)   | 66.7 (88/132)        | < 0.0001|
| UAE and Kuwait (n=299)| 49.5 (135/273)| 44.9 (105/234)      | 40.0 (2/5)     | 82.4 (28/34)         | < 0.0001|
| Saudi Arabia (n=1263)| 32.5 (388/1194)| 26.4 (276/1045) | 52.9 (9/17)    | 78.0 (103/132)       | < 0.0001|
| South Africa (n=1029)| 48.6 (478/984)| 39.9 (288/722)      | 66.7 (60/90)   | 75.6 (130/172)       | < 0.0001|

### Asia

| China (n=22,369)| 31.4 (7006/22,345)| 23.9 (4067/17,022) | 46.4 (687/1481) | 58.6 (2252/3842) | < 0.0001|
| Total (n=57,885)| 28.1 (15,533/55,227)| 21.7 (9097/41,953) | 38.0 (1377/3623) | 52.4 (5059/9651) | < 0.0001|

\(a\) Corresponding LDL-C targets for very high-, high- and non-high-risk patients were < 70 mg/dl, < 100 mg/dl and 115 mg/dl, respectively.

1. **Data**

Table 1 displays the proportion of patients attaining risk based target LDL-C values in a global cohort, overall and divided by country and region of the world. Table 2 displays the median distance to risk based treatment targets in a global cohort, overall and divided by country and region of the world.

2. **Experimental design, materials and methods**

The methodology for DYSIS (a cross-sectional, observational, multicenter registry) has been described elsewhere [1]. Briefly, statin-treated (mono/combination therapy) outpatients were consecutively enrolled at multiple centers located in 30 different countries worldwide. The study was approved by the relevant ethics committees and carried out in agreement with local laws.

Inclusion criteria were as follows: 1) provision of written informed consent, 2) availability of a fasting blood lipid profile taken within 6–12 months of study entry, at which time the participant had been on statin therapy for a minimum of 3 months 3) aged ≥ 45 years and on statin therapy at time of inclusion 4) not participating in a clinical trial.

The 2011 ESC/EAS guidelines on treatment of dyslipidemia were used for stratification of patients into risk categories [2]. Patients considered at “very high risk” of cardiovascular events were those...
### Table 2
Median distance to treatment targets.

| Country (n)               | Total\(^a\) mg/dl (IQR) | Very high-risk\(^b\) mg/dl (IQR) | High-risk\(^b\) mg/dl (IQR) | Non-high-risk\(^b\) mg/dl (IQR) | P-value |
|---------------------------|--------------------------|----------------------------------|-----------------------------|----------------------------------|---------|
| **Europe/Canada/Israel**  |                          |                                  |                             |                                  |         |
| Austria (n=881)           | 33.0 (18.0, 58.0)         | 33.0 (19.0, 58.0)                 | 31.0 (9.0, 67.0)             | 25.5 (9.0, 56.0)                 | 0.06    |
| Baltics (n=1797)          | 42.1 (20.5, 71.9)         | 42.5 (21.6, 73.9)                 | 33.0 (12.9, 69.4)            | 38.1 (15.3, 60.9)                | < 0.05  |
| Belgium (n=909)           | 24.3 (11.0, 44.0)         | 27.5 (14.0, 47.0)                 | 14.5 (7.0, 30.0)             | 14.0 (5.0, 33.5)                 | < 0.0001|
| Canada (n=2436)           | 18.8 (8.5, 34.4)          | 18.9 (8.5, 34.4)                  | 17.7 (6.3, 33.4)             | 17.1 (8.4, 31.9)                 | 0.79    |
| Denmark (n=933)           | 24.2 (11.2, 42.1)         | 26.7 (13.9, 42.1)                 | 22.6 (8.3, 46.9)             | 16.5 (4.9, 28.9)                 | < 0.01  |
| France (n=4192)           | 35.0 (18.0, 58.0)         | 38.0 (19.0, 61.0)                 | 36.5 (17.0, 61.0)            | 28.0 (15.0, 48.0)                | < 0.0001|
| Germany (n=4216)          | 38.0 (20.0, 60.0)         | 39.0 (22.0, 62.0)                 | 31.0 (14.8, 54.0)            | 28.1 (15.0, 45.9)                | < 0.0001|
| Greece (n=755)            | 37.0 (20.0, 60.0)         | 40.0 (22.0, 65.0)                 | 35.0 (21.0, 50.0)            | 28.0 (15.0, 50.0)                | < 0.01  |
| Ireland (n=900)           | 25.5 (11.2, 46.0)         | 26.7 (12.6, 46.0)                 | 26.8 (14.7, 44.4)            | 19.6 (8.7, 38.1)                 | 0.13    |
| Israel (n=100)            | 21.0 (9.0, 38.0)          | 21.3 (9.0, 39.0)                  | 23.0 (12.0, 29.0)            | 13.0 (7.0, 29.0)                 | 0.13    |
| Italy (n=766)             | 29.0 (13.0, 53.0)         | 32.0 (17.0, 55.5)                 | 22.5 (7.0, 61.5)             | 22.0 (9.0, 37.0)                 | < 0.001 |
| The Netherlands (n=1199)  | 26.7 (11.6, 42.5)         | 26.7 (11.2, 42.1)                 | 27.6 (13.7, 46.9)            | 31.8 (10.1, 39.7)                | 0.83    |
| Norway (n=957)            | 30.5 (15.1, 49.9)         | 30.5 (18.9, 51.0)                 | 16.0 (4.4, 31.7)             | 16.5 (4.9, 47.4)                 | < 0.0001|
| Portugal (n=910)          | 39.5 (21.0, 60.0)         | 42.0 (23.0, 65.0)                 | 35.0 (23.0, 56.0)            | 33.0 (16.0, 54.0)                | 0.01    |
| Russia (n=1585)           | 38.3 (18.9, 63.0)         | 38.3 (18.9, 65.0)                 | 26.8 (8.3, 66.7)             | 28.5 (10.3, 42.4)                | < 0.01  |
| Slovakia (n=926)          | 37.1 (18.2, 65.3)         | 38.7 (19.3, 68.4)                 | 35.3 (16.4, 66.7)            | 18.8 (8.0, 31.9)                 | < 0.0001|
| Slovenia (n=766)          | 38.3 (18.9, 69.2)         | 39.2 (18.9, 69.2)                 | 23.7 (12.1, 54.7)            | 30.8 (16.5, 47.4)                | 0.05    |
| Spain (n=3664)            | 39.0 (20.0, 64.0)         | 42.0 (23.0, 69.0)                 | 39.5 (19.5, 61.0)            | 32.0 (14.0, 54.0)                | < 0.0001|
| Sweden (n=958)            | 26.7 (15.1, 46.0)         | 26.7 (15.1, 46.0)                 | 27.6 (12.1, 46.9)            | 12.6 (8.7, 22.3)                 | < 0.01  |
| UK (n=1315)               | 19.3 (11.2, 36.3)         | 19.3 (11.2, 35.6)                 | 28.4 (4.4, 40.8)             | 24.2 (4.9, 51.3)                 | 0.98    |
| **Middle East/Africa**    |                          |                                  |                             |                                  |         |
| Egypt (n=1457)            | 40.0 (20.0, 71.0)         | 42.0 (20.0, 75.0)                 | 38.5 (22.0, 65.0)            | 29.0 (13.0, 47.0)                | < 0.01  |
| Lebanon/Jordan (n=603)    | 30.0 (13.0, 58.0)         | 30.0 (13.0, 59.5)                 | 25.5 (11.0, 37.0)            | 27.0 (13.5, 57.5)                | 0.37    |
| UAE and Kuwait (n=299)     | 25.0 (9.0, 41.0)          | 25.0 (9.0, 42.0)                  | 23.0 (2.0, 88.0)             | 11.5 (5.0, 24.0)                 | 0.42    |
| Saudi Arabia (n=1263)     | 34.0 (15.1, 56.0)         | 37.0 (17.0, 57.6)                 | 35.1 (7.0, 21.4)             | 11.0 (6.0, 22.0)                 | < 0.0001|
| South Africa (n=1029)     | 30.3 (14.3, 52.6)         | 30.5 (14.3, 53.7)                 | 25.1 (13.7, 43.1)            | 34.7 (13.0, 53.2)                | 0.54    |
| **Asia**                  |                          |                                  |                             |                                  |         |
| China (n=22,369)          | 33.1 (15.5, 56.8)         | 34.8 (16.6, 59.5)                 | 24.9 (11.8, 45.8)            | 24.2 (10.7, 43.5)                | < 0.0001|
| Total (n=57,885)          | 33.0 (15.8, 57.0)         | 34.4 (17.0, 59.0)                 | 28.0 (12.1, 51.2)            | 25.8 (12.0, 47.0)                | < 0.0001|

\(^a\) Total refers to the distance from individual treatment targets, irrespective of group.

\(^b\) Corresponding LDL-C targets for very high-, high- and non-high-risk patients were < 70 mg/dl, < 100 mg/dl and 115 mg/dl, respectively (given distance from target is relative to these values).
diagnosed with CHD, diabetes, chronic kidney disease, and/or peripheral artery disease, whereas those with markedly elevated single risk factors such as total cholesterol ≥ 310 mg/dl or severe hypertension (SBP ≥ 180 and/or DBP ≥ 110 mmHg) were determined to be “high-risk”. All other patients were determined to be “not high-risk”. LDL-C targets of 70 mg/dl, 100 mg/dl, and 115 mg/dl were assigned to very high-, high- and non-high-risk patients, respectively, in accordance with 2011 ESC/EAS guidelines.

Serum lipid levels were obtained from the most recent blood test for each patient, and data on lipid-lowering agents (statin type, dose, and other concomitant lipid-modifying therapies) that were being taken by the patient at that time were documented. Simvastatin was used as a reference to calculate the relative potency of other statins for comparison [3]. A central web-based database at the Institut für Herzinfarktforschung, Ludwigshafen, Germany was used to collect and store the data.

The SAS© statistical package, Version 9.3 (SAS Institute, Cary, North Carolina, USA) was used for data analysis purposes. Data were processed and presented as percentages (n/N) or medians (IQR), all of which were based one the number of patients with data for a particular case available. Categorical variables were compared by Chi-squared tests and continuous variables by Mann–Whitney–Wilcoxon (two-tailed) or Kruskal–Wallis (three-tailed) tests. In terms of distance from target, a smaller value was considered to represent greater target achievement, while a larger value represented poorer target achievement. P-values ≤ 0.05 were considered significant.

Acknowledgements

The work was supported by Merck & Co., Inc., NJ, Whitehouse Station, USA. Authors of the present study would like to thank all DYSIS investigators for their contribution to the successful completion of this study.

Transparency document. Supplementary material

Transparency data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.dib.2016.09.037.

References

[1] A. Gitt, D. Lautsch, J. Ferrieres, J.J. Kastelein, H. Drexel, M. Horack, P. Brudi, P. Bramlage, F. Chazelle, V. Sazonov, B. Ambegaonkar, Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients, Atherosclerosis (2016), http://dx.doi.org/10.1016/j.atherosclerosis.2016.09.004.

[2] European Association for Cardiovascular Prevention & Rehabilitation, Z. Reiner, A.L. Catapano, G. De Backer, I. Graham, M.R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M.J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P. P. Filardi, G. Riccardi, R.F. Storey, D. Wood, Guidelines ESCCfP, Committees, ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur. Heart J. 32 (2011) 1769–1818.

[3] W.C. Roberts, The rule of 5 and the rule of 7 in lipid-lowering by statin drugs, Am. J. Cardiol. 80 (1997) 106–107.